AEBP1 (AE binding protein 1) is a transcriptional repressor and key regulator of fibrogenesis across multiple tissues and disease contexts. Functionally, AEBP1 promotes fibroblast and myofibroblast activation, with emerging roles in inflammation and immune dysfunction. In cardiac pathology, AEBP1 is identified as a crucial regulator of cardiac fibrosis in both dilated and ischemic cardiomyopathy 1, and its knockdown promotes cardiac fibroblast activation while overexpression attenuates TGFβ-induced activation in hypertrophic cardiomyopathy 2. In cancer, fibroblast-derived AEBP1 drives T cell dysfunction through CKAP4-mediated activation of AKT/PD-L1 signaling, with therapeutic targeting enhancing antitumor immunity 3. AEBP1 also modulates pericyte-myofibroblast transformation in diabetic retinopathy, where AEBP1 knockdown reduces profibrotic markers 4. Beyond fibrosis, AEBP1 functions as a transcriptional regulator in endometriosis and type 2 diabetes, where it impairs insulin signaling through PI3K interaction and represents a therapeutic target 5. AEBP1 serves as a translatable fibrosis-associated gene across diverse organ systems including liver 6. However, AEBP1 exists as two protein isoforms (AEBP1 and ACLP) with potentially distinct functions requiring further clarification 7.